Volume 5 Supplement 6
Mortality of hospital or community-acquired Legionnaires’ disease (LD): a prospective study
© Cronenberger et al; licensee BioMed Central Ltd. 2011
Published: 29 June 2011
Introduction / objectives
The clinical aspects and outcome of hospital (HA) and community-acquired (CA) cases of LD might be different. We explored these topics in 267 patients with LD hospitalized in France.
20 HA cases and 247 CA, all being aged 60 and older infected with Legionella pneumophila serogroup 1 included in a French multicentric prospective study of LD (April/06-June/07) were compared. A confirmed HA case was defined when the entire incubation period (10 days, d) or more occurred during hospital stay, and a probable HA case was a patient hospitalized between 2d to 10d before onset. Cox regression was done to identify predictors of 30-days mortality (based on relative hazard [RH]) and survival probability was calculated using Kaplan-Meier method.
In the 20 HA, 12 (60%) were confirmed cases. No difference between the HA and CA groups was observed at admission for sex, age, smoking and alcohol habit, diabetes, respiratory, digestive, and neurological signs and intensive care unit (ICU) stay. Cancer/malignancy (45% [HA] vs 10% [CA], p<0.001), steroid therapy (35% vs 6%, p<0.001), classified in Fine score risk class IV-V (70% vs 47%, p=0.04), and mortality (45% vs 9%, p<0.001) were more prevalent in HA cases. The probability of survival at 30d was 50%, and 82% in HA and CA respectively (p<0.001). The RH of death for HA was 4.2 (95% CI 1.9-9.2; p<0.001) adjusted for age, ICU stay and renal failure.
The risk of death was higher in HA LD. Severe underlying diseases might explain such outcome. These results emphasized the need of a prompt appropriate treatment when LD is suspected in hospitalized patients.
Disclosure of interest
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.